The global generic pharmaceuticals contract manufacturing market size is valued at USD 81.24 billion in 2025 and is predicted to hit around USD 143.22 billion by 2035, rising at a 5.85% CAGR, a study ...

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Fill Finish Pharmaceutical Contract Manufacturing Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Fill Finish Service ...

The "Contract Pharmaceutical Manufacturing, Research, and Packaging Market Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering. This report aims to provide in-depth knowledge ...

What defined pharma in 2025? Contract Pharma’s most‑viewed breaking news offers insights. Here’s your yearly recap—the most ...

Symbiosis Pharmaceutical Services, a sterile fill finish contract manufacturing organization (CMO), has manufactured its first 10,000 vial batch at the company’s new facility in Stirling, UK.

SEOUL, South Korea, June 18, 2025 /PRNewswire/ -- LOTTE BIOLOGICS announced on June 19, 2025 that it has signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma, a ...

NEW YORK & MIAMI--(BUSINESS WIRE)--Aterian Investment Partners (“Aterian”), a private investment firm, is pleased to announce that one of its affiliates has entered into an agreement to recapitalize ...

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin ...

HYDERABAD (Reuters) - Indian contract drug manufacturer Suven Pharmaceuticals said on Thursday it will merge with Cohance Lifesciences in an all-share deal, as it looks to further scale up its ...

Akums Drugs & Pharmaceuticals inks MoU with Sharda University to boost industry–academia collaboration: Our Bureau, Bengaluru Monday, December 29, 2025, 16:15 Hrs [IST] Akums Dr ...

South Korea-based LOTTE BIOLOGICS signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma, a biopharmaceutical company developing PD1/VEGFR2 dual pathway antibodies ...